GlaxoSmithKline’s Emma Walmsley has grabbed headlines with some of the top management changes she’s made since taking over as CEO last March, namely poaching Luke Miels from rival AstraZeneca to head up pharmaceuticals and appointing Roche and Calico veteran Hal Barron as chief scientific officer.